Xxcorxxheaxxhcaxx B XX Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Xxcorxxheaxxhcaxx B XX Pharmaceutical Import Records from India — 2 Products, $617.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxcorxxheaxxhcaxx B XX — Pharmaceutical Importer Profile (2026) | 2 Products, $617.6K Trade | TransData Nexus

Xxcorxxheaxxhcaxx B XX

Pharmaceutical Importer · France · Oncology Focus · $617.6K Total Trade · DGFT Verified

Xxcorxxheaxxhcaxx B XX is a pharmaceutical importer based in France with a total trade value of $617.6K across 2 products in 2 therapeutic categories. Based on 15 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxcorxxheaxxhcaxx B XX sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Xxcorxxheaxxhcaxx B XX — Import Portfolio & Supplier Network

Xxcorxxheaxxhcaxx B XX import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxcorxxheaxxhcaxx B XX?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$2.7M	142	100.0%

Xxcorxxheaxxhcaxx B XX sources from 1 verified Indian supplier across 124 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Paclitaxel 6MG/ML 100ML	$150.0K	3
Pemetrexed rtu 25MG/ML	$100.0K	2
Zolsketillipodoxo 2MG/ML	$100.0K	2
Paclitaxel 6MG/ML 100ML	$100.0K	2
Azacitidine powder,150MG/v	$79.2K	3
Pregabalin 50MG 9x10c(accord-at/de	$50.0K	1
Gemcitabine100mg/ML 20ML	$50.0K	1
Gemcitabine100mg/ml20ml	$50.0K	1
Zolsketillipo doxo 2MG/ML	$50.0K	1
Temozolomid accord 100 MG	$50.0K	1
Cisplatin 1MG/ML 100ML p1	$50.0K	1
Oxaliplatinlf5mg/ML	$50.0K	1
Gemcitabine 100MG/ml20ml	$50.0K	1
Temozolomide accord	$50.0K	1
Paclitaxelinjusp 6MG/ML 50ML	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluorouracil	Oncology	$367.6K	10	3.0%	6
2	Pemetrexed	Advanced Oncology	$250.0K	5	0.9%	17

Xxcorxxheaxxhcaxx B XX imports 2 pharmaceutical products across 2 categories into France totaling $617.6K.

Xxcorxxheaxxhcaxx B XX — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxcorxxheaxxhcaxx B XX is a French pharmaceutical importer specializing in the acquisition and distribution of finished pharmaceutical formulations. Operating as a key player in France's pharmaceutical supply chain, the company sources a diverse range of pharmaceutical products to meet the needs of healthcare professionals and patients across the nation. While specific details about its headquarters and parent company are not publicly disclosed, Xxcorxxheaxxhcaxx B XX's role is pivotal in ensuring the availability of essential medications within the French market.

2Distribution Network

Xxcorxxheaxxhcaxx B XX maintains a robust distribution network with strategically located warehouses throughout France, facilitating efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are designed to support nationwide coverage, ensuring that healthcare facilities, pharmacies, and other stakeholders receive their supplies promptly. While the primary focus is on the French market, the company also explores opportunities for international distribution, leveraging its established infrastructure to expand its reach beyond national borders.

3Industry Role

In France's pharmaceutical supply chain, Xxcorxxheaxxhcaxx B XX functions as a primary wholesaler and distributor. By importing finished pharmaceutical formulations, the company bridges the gap between manufacturers and end-users, ensuring that a wide array of medications is accessible to healthcare providers and patients. This role is crucial in maintaining the flow of pharmaceutical products within the country, contributing to the overall efficiency and effectiveness of the healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxcorxxheaxxhcaxx B XX

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxcorxxheaxxhcaxx B XX demonstrates a high level of sourcing concentration, with all 15 shipments from India originating from a single supplier: Intas Pharmaceuticals Limited. This single-source dependency indicates a strategic choice, potentially aimed at ensuring consistency in product quality and supply chain reliability. However, such concentration also poses risks, including vulnerability to supply disruptions or changes in supplier dynamics. The stability of this relationship is evidenced by the consistent volume of imports, suggesting a strong and dependable partnership between Xxcorxxheaxxhcaxx B XX and Intas Pharmaceuticals Limited.

2Supply Chain Resilience

The resilience of Xxcorxxheaxxhcaxx B XX's Indian supply chain is closely tied to its exclusive partnership with Intas Pharmaceuticals Limited. While this focused sourcing strategy may streamline operations, it also means that the company has limited backup suppliers for its imported products. The diversity of formulations imported—124 unique formulations—indicates a broad product portfolio, which can mitigate risks associated with single-source dependency. However, the reliance on a single supplier for all imports suggests that any disruptions in Intas Pharmaceuticals Limited's operations could significantly impact Xxcorxxheaxxhcaxx B XX's supply chain.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). The agency is responsible for ensuring that all pharmaceutical products meet stringent safety, efficacy, and quality standards before they are authorized for sale in the French market. Key legislation governing pharmaceutical imports includes the Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from the European Medicines Agency (EMA), followed by national authorization from ANSM.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France stipulate that all imported medicines must have a valid marketing authorization issued by ANSM. Additionally, the manufacturing facilities of the exporting company must comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, WHO, or PIC/S. Indian exporters seeking to supply Xxcorxxheaxxhcaxx B XX must ensure that their manufacturing processes adhere to these GMP standards to meet the regulatory requirements for importation into France. Furthermore, wholesalers must obtain authorization from ANSM to distribute pharmaceutical products within France.

Xxcorxxheaxxhcaxx B XX — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxcorxxheaxxhcaxx B XX's focus on importing oncology and advanced oncology products aligns with the growing demand for cancer treatments in France. The substantial import values of Fluorouracil and Pemetrexed indicate a strategic emphasis on these high-demand therapeutic areas. This focus is driven by the increasing prevalence of cancer and the need for effective therapies, positioning Xxcorxxheaxxhcaxx B XX to meet critical healthcare needs within the French market.

2Sourcing Profile

Xxcorxxheaxxhcaxx B XX's sourcing strategy centers on generic drugs, particularly in the oncology sector. The exclusive partnership with Intas Pharmaceuticals Limited for all imported products suggests a preference for suppliers that can offer a comprehensive range of formulations and maintain consistent quality. India's established reputation in generic drug manufacturing makes it a strategic fit for Xxcorxxheaxxhcaxx B XX's procurement needs, ensuring access to cost-effective and high-quality pharmaceutical products.

3Market Positioning

Based on its product mix, Xxcorxxheaxxhcaxx B XX primarily serves the hospital and specialty pharmacy segments within the French market. The focus on oncology products indicates a commitment to providing critical therapies to healthcare facilities that require specialized medications for cancer treatment. This positioning underscores the company's role in supporting advanced medical care and addressing the specific needs of patients undergoing cancer treatment.

Seller's Guide — How to Become a Supplier to Xxcorxxheaxxhcaxx B XX

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Xxcorxxheaxxhcaxx B XX's supply chain, particularly if they can offer a diverse range of oncology formulations and demonstrate compliance with EU GMP standards. Gaps in Xxcorxxheaxxhcaxx B XX's current sourcing include potential vulnerabilities due to single-source dependency. New suppliers can address these gaps by providing alternative sources for critical products, thereby enhancing supply chain resilience and offering Xxcorxxheaxxhcaxx B XX more flexibility in its procurement strategy.

2Requirements & Qualifications

Indian exporters aiming to supply Xxcorxxheaxxhcaxx B XX and the French market must ensure their manufacturing facilities are certified with EU GMP, WHO GMP, or PIC/S standards. Products must undergo batch testing and meet stability requirements to ensure safety and efficacy. Labeling must be in French, with clear information on dosage, administration, and potential side effects. Additionally, compliance with serialization mandates is essential to prevent counterfeit products from entering the supply chain.

3How to Approach

Frequently Asked Questions — Xxcorxxheaxxhcaxx B XX

What products does Xxcorxxheaxxhcaxx B XX import from India?

Xxcorxxheaxxhcaxx B XX imports 2 pharmaceutical products across 2 categories. Top imports: Fluorouracil ($367.6K), Pemetrexed ($250.0K).

Who supplies pharmaceuticals to Xxcorxxheaxxhcaxx B XX from India?

Xxcorxxheaxxhcaxx B XX sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $2.7M).

What is Xxcorxxheaxxhcaxx B XX's total pharmaceutical import value?

Xxcorxxheaxxhcaxx B XX's total pharmaceutical import value from India is $617.6K, based on 15 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxcorxxheaxxhcaxx B XX focus on?

Xxcorxxheaxxhcaxx B XX imports across 2 categories. The largest: Oncology (59.5%), Advanced Oncology (40.5%).

Get Full Xxcorxxheaxxhcaxx B XX Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.